YOLFTbeta
30

Hybio Pharmaceutical

300199 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

22.79CNY-0.26 (-1.13%)

Price History

Full chart

Market Stats

Previous Close23.05
Open23.15
Day Range22.70 – 23.85
52-Week Range16.23 – 27.70
Volume38.24M
Market Cap21.13B
P/E (TTM)159.47
Forward P/E97.09
EPS0.15
Dividend Yield0.00%
Beta0.72
50-Day Avg23.14
200-Day Avg21.19

About

Hybio Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of pharmaceutical products in China and internationally. The company offers finished dosage form (FDF) products for obstetrics and gynecology, haemostatic agent, digestive tract and metabolic systems, immune system modulation, cardiovascular, diabetes mellitus, and osteoporosis, as well as medical devices comprising disposable injectable pens; and peptide active pharmaceutical ingredients (API) comprising polypeptides, small molecules and nucleic acids, and intermediates for endocrine, nutritional, and metabolic diseases; digestive system diseases; neoplasms; nervous system diseases; pregnancy, childbirth, and puerperium; musculoskeletal system and connective tissue diseases; infectious and parasitic diseases; circulatory system diseases; blood and hematopoietic organ diseases; mental and behavioral disorders; tumor; urogenital system diseases; and genitourinary system diseases, as well as factors influencing health status. It also provides contract research, development, and manufacturing organization (CRDMO) services for peptide APIs, peptide formulations, oligonucleotide drugs, and pharmaceutical intermediates. In addition, the company engages in the provision of property services, technical services, technology development, technical consulting, technical exchange, technology transfer, and technology promotion, as well as non-residential real estate leasing. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Wuhan, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Shaogui Zeng
  • Employees1.23K
  • HeadquartersHanyu Innovation Industry Building, Wuhan, China, 518110, China
  • Websitehttps://www.hybio.com.cn

Leadership

  • Mr. Shaogui ZengPresident & Chairman · b. 1968
  • Mr. Honghong TuVP & CFO · b. 1976
  • Ms. Min ZhangVice President of HR, Corporate Management & Administrative Department · b. 1980
  • Mr. Yangming TangVP & Director · b. 1978

Financials

Income Statement

Currency: CNY2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue56.20M77.36M92.71M121.93M163.00M222.93M301.40M419.43M768.26M855.05M1.25B1.26B614.19M721.72M735.97M704.32M431.38M590.20M966.35M
Growth (%)-+37.65%+19.85%+31.51%+33.68%+36.77%+35.20%+39.16%+83.17%+11.30%+45.75%+1.46%-51.43%+17.51%+1.97%-4.30%-38.75%+36.82%+63.73%
Cost of Revenue24.80M24.77M20.35M29.46M38.58M46.72M46.21M71.97M146.75M169.83M197.04M184.33M133.91M153.54M271.88M194.83M260.42M281.47M402.36M
Gross Profit31.41M52.59M72.36M92.47M127.10M176.21M255.19M347.46M621.51M685.22M1.05B1.08B480.28M568.18M464.10M509.49M170.97M308.73M564.00M
Gross Margin55.88%67.99%78.05%75.84%77.98%79.04%84.67%82.84%80.90%80.14%84.19%85.42%78.20%78.73%63.06%72.34%39.63%52.31%58.36%
Operating Expense14.11M27.59M32.53M40.39M63.22M93.67M112.97M164.15M292.58M407.36M694.79M1.40B1.39B1.14B425.00M880.30M678.47M470.11M345.46M
Operating Income17.30M25.01M39.83M52.08M63.88M82.54M142.22M183.31M328.93M277.85M354.40M-320.32M-905.31M-574.36M39.10M-370.80M-507.50M-161.39M218.53M
Operating Margin30.78%32.32%42.96%42.71%39.19%37.02%47.19%43.71%42.82%32.50%28.44%-25.33%-147.40%-79.58%5.31%-52.65%-117.65%-27.34%22.61%
EBITDA15.09M25.33M43.03M52.08M101.00M116.04M147.77M214.75M434.15M442.45M476.25M307.53M-393.34M-440.71M-144.93M-52.60M-222.64M113.52M295.01M
EBITDA Margin26.85%32.74%46.41%42.71%61.96%52.05%49.03%51.20%56.51%51.75%38.21%24.32%-64.04%-61.06%-19.69%-7.47%-51.61%19.23%30.53%
Net Income15.23M19.86M35.37M52.85M80.47M89.80M129.93M171.56M305.34M291.92M329.72M-340.78M-884.77M-609.43M30.81M-370.55M-513.88M-173.65M36.57M
Net Income Margin27.10%25.67%38.15%43.34%49.37%40.28%43.11%40.90%39.74%34.14%26.46%-26.95%-144.05%-84.44%4.19%-52.61%-119.12%-29.42%3.78%
R&D-8.93M8.83M15.15M14.60M24.56M34.73M46.03M51.79M60.37M89.42M94.89M180.31M143.93M105.68M158.68M161.50M88.01M126.85M
R&D as % of Total Revenue-11.54%9.52%12.42%8.96%11.02%11.52%10.97%6.74%7.06%7.17%7.50%29.36%19.94%14.36%22.53%37.44%14.91%13.13%
Interest Expense-1.39M0616.19K68.02K73.67K90.23K11.83M33.67M40.75M25.87M48.42M94.50M65.35M99.72M109.71M125.77M117.94M98.04M
Interest Expense % of Total Revenue-1.80%0.00%0.51%0.04%0.03%0.03%2.82%4.38%4.77%2.08%3.83%15.39%9.05%13.55%15.58%29.15%19.98%10.14%

Balance Sheet

Currency: CNY2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets58.24M136.55M182.47M212.89M1.04B1.12B1.29B1.70B3.55B4.46B5.30B5.66B4.72B4.04B3.91B3.61B3.28B3.01B3.15B
Total Liabilities9.54M37.32M54.73M32.30M62.91M107.42M164.48M401.32M908.68M852.42M1.41B2.27B2.49B2.36B2.26B2.31B2.49B2.41B2.52B
Total Equity48.70M99.23M127.74M180.59M972.73M1.02B1.12B1.30B2.64B3.60B3.88B3.39B2.23B1.64B1.58B1.27B758.80M578.63M613.95M
Cash1.77M44.59M81.04M83.57M793.13M617.10M447.49M700.06M186.90M880.54M1.27B1.56B820.77M451.65M138.92M106.26M344.01M94.87M100.72M
Total Debt--29.00M----198.76M497.75M417.74M774.85M1.76B1.91B1.74B1.71B1.34B1.56B1.50B-
Net Debt-1.77M-44.59M-52.04M-83.57M-793.13M-617.10M-447.49M-501.30M310.85M-462.80M-493.62M192.76M1.09B1.29B1.57B1.23B1.21B1.41B1.56B

Cash Flow

Currency: CNY2007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow49.04M45.75M26.11M54.69M72.48M87.19M153.48M153.43M138.84M296.41M228.56M47.00M104.64M47.99M156.83M15.81M-3.54M164.71M233.90M
Investing Cash Flow1.24M-55.58M-9.01M-22.83M-78.04M-220.57M-302.85M-85.16M-1.12B-131.01M-223.49M-419.86M-595.99M-258.47M-178.39M51.72M147.71M-70.01M-
Financing Cash Flow-48.89M53.07M20.25M-30.55M716.19M-42.31M-18.92M184.10M466.80M524.41M393.19M654.58M-425.20M-71.68M-253.67M-71.11M95.85M-345.48M-
Capital Expenditure4.90M60.28M9.01M22.83M78.27M221.38M302.85M85.16M358.98M116.05M221.14M365.58M570.15M243.66M199.00M189.85M81.76M115.84M234.35M
Free Cash Flow44.14M-14.53M17.10M31.87M-5.79M-134.19M-149.38M68.26M-220.14M180.36M-7.39M-318.58M-465.52M-195.67M-42.17M-174.04M-85.30M48.87M-449.75K
Dividends Paid-17.21M30.90M1.55M-46.45M18.92M8.50M74.30M63.14M128.30M252.77M114.59M104.96M115.64M114.80M117.90M111.75M94.84M
FCF to OCF90.02%-31.76%65.51%58.27%-7.99%-153.91%-97.33%44.49%-158.56%60.85%-3.24%-677.85%-444.89%-407.73%-26.89%-1101.00%2411.91%29.67%-0.19%
Dividend Paid to FCF--118.46%180.67%4.87%--34.61%-12.67%12.45%-33.75%35.01%-1735.02%-79.34%-24.62%-53.64%-274.23%-65.96%-138.22%228.66%-21086.49%

Earnings

Report DateApr 24, 2013Sep 3, 2014Oct 27, 2014Mar 1, 2015Apr 22, 2015Aug 12, 2015Oct 21, 2015Feb 25, 2016Apr 27, 2016Aug 3, 2016Oct 26, 2016Feb 27, 2017Apr 26, 2017Aug 16, 2017Oct 25, 2017Feb 28, 2018Apr 25, 2018Aug 7, 2018Oct 24, 2018Feb 27, 2019Apr 24, 2019Aug 28, 2019Oct 24, 2019Feb 28, 2020Apr 29, 2020Aug 14, 2020Oct 27, 2020Apr 28, 2021Aug 28, 2021Oct 29, 2021Apr 28, 2022Aug 27, 2022Oct 29, 2022Apr 27, 2023Aug 15, 2023Oct 30, 2023Apr 26, 2024Aug 24, 2024Oct 29, 2024Apr 25, 2025Aug 22, 2025Oct 29, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate0.02-0.050.070.030.150.070.080.110.070.130.20--0.230.200.200.20-0.17-0.070.100.04---------------------
EPS Actual0.020.030.080.090.080.060.090.190.140.060.130.080.090.090.070.080.110.120.09-0.690.060.03-0.17-0.870.030.030.01-0.73-0.06-0.100.17-0.05-0.060.02-0.06-0.17-0.020.00-0.030.080.09-0.08-0.040.140.12
Surprise0.00%-60.00%28.57%166.67%-60.00%28.57%137.50%27.27%-14.29%0.00%-60.00%---69.57%-60.00%-45.00%-40.00%--505.88%--57.14%-270.00%-2275.00%---------------------
TimingAfter-hours-After-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-market--Pre-market-----After-hours-Pre-marketPre-market-----

Key Statistics & Ratios

Market Cap21.13B
Enterprise Value23.22B
Trailing P/E159.47
Forward P/E97.09
PEG Ratio0.00
Price / Sales19.12
Price / Book25.23
EPS0.15
Book Value0.963
Revenue (TTM)1.11B
Gross Profit (TTM)622.69M
EBITDA332.63M
Profit Margin11.56%
Operating Margin30.24%
Return on Equity15.58%
Return on Assets3.42%
Shares Outstanding883.24M
Shares Float651.67M
Beta0.72
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20181×
0.20Apr 19, 2018
20171×
0.10Jun 22, 2017
20161×
0.03Jun 2, 2016
20151×
0.05Apr 14, 2015
20131×
0.05Apr 26, 2013
20121×
0.06May 17, 2012

Stock Splits

  • Apr 14, 201520:10
  • Apr 26, 201320:10
  • May 17, 201220:10